



## PRESSEINFORMATION

### **Strong demand for BRAIN shares from institutional investors**

Zwingenberg  
August 29, 2017

**Zwingenberg, August 29, 2017: B.R.A.I.N. Biotechnology Research and Information Network AG („BRAIN AG“; ISIN DE0005203947 / WKN 520394) was informed by Green Industries Group GmbH & Co. KG that on August 24, 2017, it sold a block of 1.21 million shares from its portfolio over the counter in several OTC transactions to institutional investors. According to information from the managing director of Green Industries Group GmbH & Co. KG, Dr Holger Zinke, the transaction of the investment company, which has been a shareholder of BRAIN AG since 2011, was carried out by Steubing AG Wertpapierhandelsbank Frankfurt/Main. At the same time, the main shareholder of BRAIN AG, MP Beteiligungs-GmbH, has taken over 88,257 shares. As a result of the placement, the free float of the BRAIN share increases further from 42% to now 49%.**

Dr Jürgen Eck, CEO of BRAIN AG, is pleased with the interest of investors in the BRAIN share: "The Green Industries Group GmbH & Co. KG has been committed to the growth of BRAIN AG for many years and has thus also played an important role in the positive development of BRAIN. I would therefore like to express my gratitude for the very good and always trustworthy cooperation in recent years. Through the placement, the free float of the BRAIN share has significantly increased, which will also further improve the liquidity of the share for all investors."

**B·R·A·I·N**  
Biotechnology Research  
And Information Network AG  
Darmstädter Str. 34-36  
64673 Zwingenberg  
Germany  
[www.brain-biotech.de](http://www.brain-biotech.de)

Contact Investor Relations  
Dr. Martin Langer  
Executive Vice President  
Corporate Development  
Tel.: +49-(0)-6251-9331-16  
Fax: +49-(0)-6251-9331-11  
E-Mail: [ir@brain-biotech.de](mailto:ir@brain-biotech.de)



## About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this „Toolbox of Nature“ are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars – BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at [www.brain-biotech.de/en](http://www.brain-biotech.de/en).

## Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.